{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T16:46:23Z","timestamp":1777999583335,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s13555-023-00965-5","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T13:02:44Z","timestamp":1691499764000},"page":"2107-2120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Alexa B.","family":"Kimball","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimittri","family":"Delevry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chia","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"B\u00e9go-Le-Bagousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Sierka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"issue":"2","key":"965_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","volume":"77","author":"L Eckert","year":"2017","unstructured":"Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the national health and wellness survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"965_CR2","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/jdv.16003","volume":"34","author":"M de Bruin-Weller","year":"2020","unstructured":"de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026\u201336.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"965_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s13555-022-00700-6","volume":"12","author":"T Luger","year":"2022","unstructured":"Luger T, Romero WA, Gruben D, Smith TW, Cha A, Neary MP. Clinical and humanistic burden of atopic dermatitis in Europe: analyses of the national health and wellness survey. Dermatol Ther (Heidelb). 2022;12(4):949\u201369.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"965_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s13555-021-00580-2","volume":"11","author":"P Anderson","year":"2021","unstructured":"Anderson P, Austin J, Lofland JH, Piercy J, Joish VN. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among US patients receiving topical therapy for atopic dermatitis. Dermatol Ther (Heidelb). 2021;11(5):1571\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"965_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.anai.2019.07.008","volume":"123","author":"W Wei","year":"2019","unstructured":"Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy Asthma Immunol. 2019;123(4):381\u20138.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"965_CR6","unstructured":"Regeneron Pharmaceuticals Inc., Sanofi-Aventis US LLC.  DUPIXENT\u00ae [dupilumab injection for subcutaneous use]: prescribing information. Available from: https:\/\/www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf. Accessed October 2022."},{"issue":"3","key":"965_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","volume":"23","author":"LA Beck","year":"2022","unstructured":"Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393\u2013408.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"965_CR8","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.xjidi.2021.100042","volume":"1","author":"M Kamata","year":"2021","unstructured":"Kamata M, Tada Y. A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov. 2021;1(3):100042.","journal-title":"JID Innov"},{"issue":"2","key":"965_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamadermatol.2021.4778","volume":"158","author":"B Strober","year":"2022","unstructured":"Strober B, Mallya UG, Yang M, et al. Treatment outcomes associated with dupilumab use in patients with atopic dermatitis: 1-year results from the RELIEVE-AD Study. JAMA Dermatol. 2022;158(2):142\u201350.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"965_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-019-0095-3","volume":"19","author":"E Simpson","year":"2019","unstructured":"Simpson E, Eckert L, Gadkari A, et al. Validation of the atopic dermatitis control tool (ADCT(\u00a9)) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15.","journal-title":"BMC Dermatol"},{"issue":"3","key":"965_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the atopic dermatitis control tool (ADCT). Curr Med Res Opin. 2020;36(3):367\u201376.","journal-title":"Curr Med Res Opin"},{"key":"965_CR12","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"issue":"1","key":"965_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"key":"965_CR14","unstructured":"Reilly MC. Work Productivity and Activity Impairment Questionnaire for Atopic Dermatitis. www.reillyassociates.net\/WPAI-AtopicDermatitis-v2-English-US-Original.doc. Accessed 21 Mar 2023."},{"issue":"1","key":"965_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1037\/1082-989X.2.1.64","volume":"2","author":"D Hedeker","year":"1997","unstructured":"Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods. 1997;2(1):64\u201378.","journal-title":"Psychol Methods"},{"issue":"2","key":"965_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records. Int J Dermatol. 2020;59(2):253\u20136.","journal-title":"Int J Dermatol"},{"issue":"2","key":"965_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.18176\/jiaci.0641","volume":"32","author":"E Nettis","year":"2022","unstructured":"Nettis E, Ferrucci SM, Ortoncelli M, et al. Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol. 2022;32(2):124\u201332.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"965_CR18","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.jaad.2020.02.029","volume":"82","author":"CE Jo","year":"2020","unstructured":"Jo CE, Georgakopoulos JR, Ladda M, et al. Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate-to-severe atopic dermatitis in clinical practice: a retrospective cohort study. J Am Acad Dermatol. 2020;82(6):1530\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"3 suppl","key":"965_CR19","doi-asserted-by":"publisher","first-page":"AB32","DOI":"10.1016\/j.jaad.2021.06.155","volume":"85","author":"J Bagel","year":"2021","unstructured":"Bagel J, Yosipovitch G, Pariser D, et al. Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: real-world data from the PROSE registry [abstract]. J Am Acad Dermatol. 2021;85(3 suppl):AB32.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"965_CR20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s13555-022-00731-z","volume":"12","author":"LF Eichenfield","year":"2022","unstructured":"Eichenfield LF, Armstrong A, Guttman-Yassky E, et al. Real-world effectiveness of dupilumab in atopic dermatitis patients: analysis of an electronic medical records dataset. Dermatol Ther (Heidelb). 2022;12(6):1337\u201350.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"965_CR21","first-page":"228","volume":"157","author":"M Napolitano","year":"2022","unstructured":"Napolitano M, Fabbrocini G, Nocerino M, Potestio L, Patruno C. The effects of dupilumab treatment on general health-related work productivity of adult atopic patients. Ital J Dermatol Venerol. 2022;157(3):228\u201330.","journal-title":"Ital J Dermatol Venerol"},{"issue":"2","key":"965_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00403-021-02214-1","volume":"314","author":"MR Hong","year":"2022","unstructured":"Hong MR, Lei D, Yousaf M, et al. A real-world study of the longitudinal course of itch severity and frequency in adults with atopic dermatitis. Arch Dermatol Res. 2022;314(2):141\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"965_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/ced.14948","volume":"47","author":"G Schwartzman","year":"2022","unstructured":"Schwartzman G, Lei D, Ahmed A, Chavda R, Gabriel S, Silverberg JI. Longitudinal course and phenotypes of health-related quality of life in adults with atopic dermatitis. Clin Exp Dermatol. 2022;47(2):359\u201372.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"965_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1089\/DERM.0000000000000859","volume":"34","author":"J Manjunath","year":"2023","unstructured":"Manjunath J, Lei D, Ahmed A, et al. Longitudinal course of sleep disturbance and relationship with itch in adult atopic dermatitis in clinical practice. Dermatitis. 2023;34(1):42\u201350.","journal-title":"Dermatitis"},{"issue":"9","key":"965_CR25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.2340\/00015555-3212","volume":"99","author":"LFM Ariens","year":"2019","unstructured":"Ariens LFM, van Nimwegen KJM, Shams M, et al. Economic burden of adult patients with moderate to severe atopic dermatitis indicated for systemic treatment. Acta Derm Venereol. 2019;99(9):762\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"965_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13555-020-00459-8","volume":"11","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, Luger T, Nosbaum A, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2021;11(1):117\u201330.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"965_CR27","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/1346-8138.14116","volume":"45","author":"W Wei","year":"2018","unstructured":"Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate-to-severe atopic dermatitis. J Dermatol. 2018;45(2):150\u20137.","journal-title":"J Dermatol"},{"issue":"8","key":"965_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","volume":"154","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903\u201312.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"965_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","volume":"126","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Guttman-Yassky E, Gadkari A, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):40\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"965_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdin.2021.06.001","volume":"4","author":"JR Georgakopoulos","year":"2021","unstructured":"Georgakopoulos JR, Felfeli T, Drucker AM, Jo CE, Piguet V, Yeung J. Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: a real-world Canadian multicenter retrospective study. JAAD Int. 2021;4:67\u20139.","journal-title":"JAAD Int"},{"issue":"5","key":"965_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00965-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T19:09:28Z","timestamp":1692644968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00965-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00965-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}